Clinical Scorecard: Impact of Lymph Node Status on Outcomes in Resectable Non-Metastatic Solid Pseudopapillary Tumors of the Pancreas: Insights from a SEER Population Analysis

At a Glance

Key Highlights

• SPTs are rare pancreatic neoplasms with generally favorable prognosis after resection, with a 5-year overall survival of 96.2%.
• Positive lymph node status, higher lymph node ratio, advanced age, and tumor location (head or body) are significant independent predictors of worse overall survival.
• Most patients do not receive chemotherapy or radiotherapy postoperatively; surgical resection remains the primary treatment modality.

Guideline-Based Recommendations

Diagnosis

• Confirm diagnosis using histology code 8452/3 (SPT) and pancreatic site code C25 per ICD-O-3 classification.
• Perform adequate lymphadenectomy during surgery to assess lymph node status accurately.

Management

• Radical surgical resection is the mainstay of treatment for resectable non-metastatic SPTs.
• Routine postoperative chemotherapy and radiotherapy are generally not administered given the favorable prognosis.

Monitoring & Follow-up

• Monitor overall survival and recurrence risk with attention to lymph node involvement and tumor location.
• Use AJCC 8th edition staging criteria for pathological staging and risk stratification.

Risks

• Positive lymph node involvement and higher lymph node ratio significantly increase risk of worse survival outcomes.
• Older age at diagnosis is associated with poorer prognosis.

Patient & Prescribing Data

293 patients with resectable, non-metastatic pancreatic SPTs who underwent surgery with adequate lymphadenectomy

Majority (over 97%) did not receive chemotherapy or radiotherapy postoperatively; surgical resection with lymph node assessment is critical for prognosis.

Clinical Best Practices

• Ensure adequate lymphadenectomy during surgical resection to accurately stage lymph node involvement.
• Consider patient age and tumor location in prognostic assessment and counseling.
• Utilize population-based data to guide risk stratification and individualized patient management.
• Follow AJCC 8th edition staging guidelines for consistent pathological staging.

References

• SEER Program - Surveillance, Epidemiology, and End Results
• ICD-O-3 Classification
• AJCC 8th Edition Staging Manual for Pancreatic Cancer